Boehringer Ingelheim 2010b

Methods	Randomised clinical trial
Participants	10 adult participants Inclusion criteria: with diagnosis of cirrhosis and chronic HCV (genotype 1) infection with a VL greater than 50,000 copies mRNA/ml serum. Country: Germany
Interventions	Experimental group: oral 200 mg twice daily for 2 days. Control group: placebo.
Outcomes	Efficacy assessment, safety assessment
Notes	Unpublished data only
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	The trial was described as being double‐blinded but it was unclear how the blinding was performed
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	The trial was described as being double‐blinded but it was unclear how the blinding was performed
Incomplete outcome data (attrition bias) All outcomes	Low risk	There were no dropouts
Selective reporting (reporting bias)	Unclear risk	No protocol could be obtained
Vested‐interest bias	High risk	The trial was funded by Boehringer Ingelheim
Other bias	Low risk	The trial appeared to be free of other components that could put it at risk of bias